VRTX

ACCE thesis

Vertex owns the cystic fibrosis market with its triple-combination therapy Trikafta, treating 90% of CF patients and generating $9.9 billion in 2023 revenue. The company's expertise in rare disease drug development creates massive barriers to entry, with Trikafta alone treating a patient population that competitors abandoned as too small and scientifically challenging. Vertex is advancing VX-548, a non-opioid pain medication targeting Nav1.8 channels, into Phase 3 trials for acute pain with results expected in 2025. Trading at 20x forward earnings despite 22.5% ROE, the stock offers exposure to a franchise that prints cash while building the next generation of breakthrough therapies. Management expects Trikafta revenue to plateau around $10-11 billion, but the pain program alone addresses a $15 billion addressable market.

• moderate
  Revenue growth deceleration

  YoY revenue growth slowed to +7.8% vs 5-year CAGR of +27.7%, signaling meaningful deceleration in core business momentum.
• moderate
  Negative sequential revenue

  QoQ revenue growth of -6.4% suggests near-term softness; worth monitoring for trend continuation in coming quarters.
• moderate
  Insider selling, no buying

  Last 10 disclosed transactions show $5.16M in sales and zero buys, indicating insiders are not adding exposure at current prices.

Snapshot